Determination of CD4+ cell count and viral load in hiv-positive patients as possible indicators of art effectiveness
DOI:
https://doi.org/10.5281/zenodo.20008155Keywords:
CD4 count, Viral Load, Human Immunodeficiency Virus, Anti Retroviral TreatmentAbstract
The introduction of antiretroviral therapy (ART) among patients formerly naïve to treatment leads to suppression of HIV replication and CD4+ cell count recovery. The global response to end Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) by 2030 is critically dependent on effective viral load (VL) monitoring and management cluster of differentiation 4 (CD4+) cell count recovery after initiation of ART is a potential indicator of HIV patient’s clinical outcome and an increase in CD4+ cell count indicates a favourable outcome related with both AIDS and non–AIDS-related conditions and the improvement in life expectancy. Early initiation of antiretroviral therapy (ART) is essential for suppressing viral replication, enhancing immune function, and reducing morbidity and mortality rates. In conclusion, CD4+ cell count failed to recover in a substantial proportion of patients initiating ART in this resource-limited setting. Therefore, novel therapeutic approaches, with good access to CD4+ cell count monitoring and a focus on those at greatest risk, are needed to maximize CD4+ cell count recovery and improve outcomes during therapy. VL suppression was low among the patients. Health promotion activities are needed for people who have been suppressed to maintain and achieve a lifetime undetectable VL, targeting the younger age group.
References
WHO: Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2010 Revision. Geneva: World Health Organization, 2010.
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss D, et al. Decline in the aids and death rates in the eurosida study: an observational study. Lancet. 2003;362(9377):22–9.
Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, Investigators HOS, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the hiv outpatient study. JAIDS J Acq Immune Defic Syndr. 2006;43(1):27–34.
Battegay M, Nu¨esch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006; 6(5):280–7.
Yamashita TE, Phair JP, Muñoz A, Margolick JB, Detels R, O’Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 2001; 15 (6):735–46.
Lokpo SY, Ofori-Attah PJ, Ameke LS, Obirikorang C, Orish VN, Kpene GE et al. Viral suppression and its associated factors in HIV patients on Highly active antiretroviral therapy (HAART): a retrospective study in the Ho Municipality, Ghana. AIDS Research and Treatment. 2020; 13:1–7.
Lecher SL, Ellenberger D, Kim AA, Fonjungo PN, Agolory S, Borget MY et al. Scale-up of HIV viral load Monitoring — Seven Sub-Saharan African countries. Morbidity and Mortality Weekly Report. 2015; 64(46):1287–90.
Hoffman J, van Johan G, Colebunders R, McKellar M. Role of the CD4 count in HIV management. HIV Therapy. 2010;4:27–39.
The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 Cell Count and the Risk of AIDS or Death in HIV Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Med. 2012; 9(3):e1001194.
Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008; 22(7):841–8.
Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS, and the Canada HIV Trials Network. CD4+ Cell Count Increase Predicts Clinical Benefits in Patients with Advanced HIV Disease and Persistent Viremia after 1 Year of Combination Antiretroviral Therapy. J Infect Dis. 2005; 192(8):1407–11.
Grabar S, Moing VL, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy. Ann Intern Med. 2000; 133:401–10.
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4R cell count and viral load response to antiretroviral therapy. AIDS. 2014; 28 (8):1193–202.
WHO: Antiretroviral Therapy for HIV Infection in Infants and Children:
Towards Universal Access. In HIV/AIDS Programme: Strengthening Health Services to Fight HIV/AIDS. World Health Organization, 2010.
Takuva S, Maskew M, Brennan AT, Long L, Sanne I, Fox MP. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014; 17(1):18651.
Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JSG. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS. 2006; 20(3):371–7.
Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study. Arch Intern Med. 2003; 163(18):2187–95.
Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on Antiretroviral Therapy (ART) in sub-Saharan Africa: Frequency and clinical significance. AIDS Res Ther. 2008; 5:23.
Yang X, Su B, Zhang X, Liu Y, Wu H, Zhang T. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders. J Leukoc Biol. 2020; 107 (4):597–612.
Nakanjako D, Kiragga AN, Musick BS, Yiannoutsos CT, Wools-Kaloustian K, Diero L, et al. Frequency and impact of suboptimal immune recovery on firstline antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. AIDS. 2016; 30(12):1913–22.
Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, et al. Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases. J Acquir Immune Defic Syndr. 2008; 48(5):541–6.
Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007; 46(1):72–7.
Gutie´ rrez F, Padilla S, Masia M, Iribarren JA, Moreno S, Viciana P, et al. Patients’ characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res. 2008; 6(2):100–7
Boatman JA, Baker JV, Emery S, Furrer H, Mushatt DM, Sedlacek D, et al. Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts >500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. J Acquir Immune Defic Syndr. 2019; 81:10–17.
Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D’Aquila RT, et al. Immunogenetics of CD4 Lymphocyte Count Recovery during Antiretroviral Therapy: An AIDS Clinical Trials Group Study. J Infect Dis. 2006; 194(8):1098–107.
Geng EH, Neilands TB, Thiebaut R, Bwana MB, Nash D, Moore RD, et al. CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. Int J Epidemiol. 2015; 44(1):251–63.
Kesselring A, Gras L, Wit FW, Reiss P, Wolf FD. Maximum capacity of restoration of CD4 counts is lower in HIV-1-infected patients from Sub-Saharan Africa during the first months of cART: the Athena cohort. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3–6 February 2008.
Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, Emenyonu NI, et al. Late disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009; 52(2):280–9.
Belay GM, Endalamaw A, Ayele AD. Late presentation of HIV positive adults and its predictors to HIV/ AIDS care in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19:534
Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003; 17:2015–2023.
Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003; 77:11708–11717.
Schacker T. The role of secondary lymphatic tissue in immune deficiency of HIV infection. AIDS. 2008; 22:S13–S18.
Estes J, Baker JV, Brenchley JM, Khoruts A, Barthold JL, Bantle A, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis. 2008; 198:456–464.
Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003; 17:1907–1915.
Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, et al. Long-term changes in
circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS. 2004; 18:1953–1956.
Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of Lopinavir- Ritonavir treatment. Clinical Infectious Diseases. 2007; 44:749–754.
Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007; 370:407–413.
Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009; 48:787–794. [PubMed: 19193107]
Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1- infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005; 41:361–372.
Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. JAIDS. 2007; 45:183–192.
Engsig FN, Zangerle R, Κατσαρού Ό, Dabis F, Reiss P, Gill MJ et al. Long-term mortality in HIV-positive individuals virally suppressed for > 3 years with incomplete CD4 recovery. Clinical Infectious Diseases. 2014; 58(9):1312–21.
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2016.
Frescura L, Godfrey-Faussett PA, AF, El‐Sadr W, Syarif O, Ghys PD. Achieving the 95-95-95 targets for all: A pathway to ending AIDS. PloS One. 2022; 17(8):e0272405. https://doi.org/10.1371/journal.pone.0272405
UNAIDS. Fast-Track: accelerating action to end the AIDS epidemic by 2030. [Internet]. 2015.
Lecher SL, Ellenberger D, Kim AA, Fonjungo PN, Agolory S, Borget MY et al. Scale-up of HIV viral load Monitoring — Seven Sub-Saharan African countries. Morbidity and Mortality Weekly Report. 2015; 64(46):1287–90.
Ghana AIDS, Commission. (2019). Ghana May Not Meet the 90-90- 90 Target by 2020–AIDS Commission. Ghana AIDS Commission Accra, Ghana
Ayisi-Boateng NK, Opoku DA, Nkrumah I, Frempong B, Owusu M, Oduro E et al. Clinical profile and predictors of viral suppression in HIV-infected older adults at a University Hospital in Kumasi, Ghana. AIDS Care. 2022; 35(12):1821–9. https://doi.org/10.1080/09540121.2022.2119468
Sheth AN, Ofotokun I, Buchacz K, Armon C, Chmiel JS, Hart R et al. Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996–2011. Journal of Acquired Immune Deficiency Syndromes. 2016; 71(1):47–56.
Kayigamba FR, Franke MF, Bakker MI, Rodriguez CA, Bagiruwigize E, Wit FW, et al. Discordant treatment responses to combination antiretroviral therapy in Rwanda: A prospective cohort study. PLoS ONE. 2016; 11(7):e0159446
Gelba SB, Fikadu S, Legesse AK, Wubet H, Yesuf MA, Abera W, et al. Assessment of Pattern of CD4+ T-Cell Recovery Among Human Immunodeficiency Virus Patients After Initiation of Highly Active Antiretroviral Therapy at Arsi Negelle Health Center, Ethiopia: A Retrospective Cross-Sectional Study. HIV AIDS. 2020; 12:69–77.
Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, Kindeya F. CD4 Cell Count Trends after Commencement of Antiretroviral Therapy among HIVInfected Patients in Tigray, Northern Ethiopia: A Retrospective Cross-Sectional Study. PLoS ONE. 2015; 10(3):e0122583.
Desta AA, Woldearegay TW, Berhe AA, Futwi N, Gebru GG, Godefay H. Immunological recovery, failure and factors associated with CD-4 T-cells progression over time, among adolescents and adults living with HIV on Antiretroviral Therapy in Northern Ethiopia: A retrospective cross sectional study. PLOS ONE. 2019; 14(12):e0226293.
Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis. 2014; 14(1):28.
Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet M-A, Ajayi S, et al. Immuno-virologic outcomes and immunovirologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013; 13:113.
Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, et al. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. AIDS. 2018; 32 (8):1043–51
Lawn SD, Myer L, Bekker L-G, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis. 2006; 6:59.
Gezie LD. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis. BMC Res Notes. 2016; 9:377.
Dronda F, Moreno S, Moreno A, Casado JL, Perez-Elias MJ, Antela A. Long-Term Outcomes among AntiretroviralNaive Human Immunodeficiency Virus–Infected Patients with Small Increases in CD4+ Cell Counts after Successful Virologic Suppression. Clin Infect Dis. 2002; 35:1005–9.
Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect. 2012; 18:449–58.
Moore RD, Keruly JC. CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic Suppression. Clin Infect Dis. 2007; 44:441–6. https://doi. org/10.1086/510746 PMID: 17205456
Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, et al. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. AIDS. 2018; 32(17):2605–14
Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009; 48(3):350–61
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Annals of Mechnikov's Institute
This work is licensed under a Creative Commons Attribution 4.0 International License.
